Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tumor neoantigen antibody
- Development stage
- Preclinical
- Lead developer
- Eliteimmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Tumor neoantigen antibody is a fully human monoclonal antibody program being developed by EliteImmune for the treatment of neoantigen-positive cancers. Isolated from rare elite controllers (patients who spontaneously control or recover from diseases), this antibody is designed to target specific tumor neoantigens—highly immunogenic, tumor-specific proteins arising from somatic mutations in cancer cells. By binding to these neoantigens, the antibody mediates passive immunotherapy to exert a targeted anti-tumor effect while sparing normal, healthy tissues.
- Other names
- Neoantigen
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Tumor neoantigen antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor neoantigen antibody.